| bibliographicCitation |
Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, Mehra P, Alpert M, Baird I, Klein S, Litow J, Marsh P, Penn R, Augustinsk J, Young D, Bunce C, Green D, Eyzaguirre R, Ambasch G, Curcio DJ, Lopardo G, Minguez AR, Oliva ME, Teglia OF, Campos M, Gaete P, Acuna G, Jansen L, Jauregui A, Perez C, Seas C, Gutierrez J, Mayorga M, Bubnova NA, Goryunov SV, Krylov KM, Macheret EA, Novozhilov AA, Zhidkov KP, Kozlov RS, Florescu IP, Orasan R, Trifu V, Ockenfels H-, Hermes B, Brockmeyer N, Dippel E, Kujath P, Kowalzick L, Ulrich J, Krasnodebski I, Jaworski R, Zaniewski M, Wallner G, Kapinska-Mrowiecka M, Dziki A, Motyka M, Borschivsky VM, Gerych ID, Lukashov SM, Pyptyuk OV, . CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy. 2010 Nov 01;65(Supplement 4):iv41–51. doi: 10.1093/jac/dkq254. |